v3.25.3
Consolidated Balance Sheets (Unaudited) - USD ($)
Sep. 30, 2025
Dec. 31, 2024
Current assets:    
Cash and cash equivalents $ 1,673,218 $ 3,502,077
Unbilled receivable 4,411 124,115
Prepaid expenses and other current assets 1,250,641 1,718,490
Total current assets 2,928,270 5,344,682
Property and equipment, net 123,643
Other assets 127,551 252,550
Total assets 3,179,464 5,597,232
Current liabilities:    
Accounts payable 463,458 1,357,079
Accrued expenses and other liabilities 1,453,555 548,458
Notes payable and accrued interest 387,702 301,660
Total current liabilities 2,304,715 2,207,197
Long-term liabilities:    
Other long-term liabilities 35 10,096
Total long-term liabilities 35 10,096
Total liabilities 2,304,750 2,217,293
Commitments and contingencies (Note 7)
Stockholders’ equity    
Preferred stock, $0.0001 par value, 1,500,000 shares authorized, no shares issued and outstanding at September 30, 2025 and December 31, 2024
Common stock, $0.0001 par value, 250,000,000 shares authorized at September 30, 2025 and December 31, 2024; 3,181,080 and 1,355,779 shares issued at  September 30, 2025 and December 31, 2024, respectively; 3,181,074 and 1,355,773  shares outstanding at September 30, 2025 and December 31, 2024, respectively 320 136
Additional paid-in capital 138,155,394 133,252,585
Accumulated deficit (136,952,351) (129,544,299)
Total Ensysce Biosciences, Inc. stockholders’ equity 1,203,363 3,708,422
Noncontrolling interests in stockholders’ equity (328,649) (328,483)
Total stockholders’ equity 874,714 3,379,939
Total liabilities and stockholders’ equity $ 3,179,464 $ 5,597,232

Source